Weitz & Luxenberg is no longer accepting Heparin cases

FDA Issues Health Advisory Regarding Heparin: Change in Reference Standard

On April 7, 2010, the U.S. Food and Drug Administration (FDA) issued the following health advisory regarding the blood thinning drug Heparin. The drug was recalled in 2008 after reports of serious injury and deaths linked to tainted sources of the drug.

If you or a loved one suffered a serious injury linked to the use of Heparin, please complete the form on this page for important information from our lawyers about your legal rights.

Audience: Pharmacists, physicians, hospital risk managers and consumers

Laboratory studies performed at the request of the FDA have shown that Heparin Sodium, USP made under the new United States Pharmacopeia (USP) Monograph ("new heparin") has approximately 10% less blood-thinning (anticoagulant) activity compared to heparin prepared using the previous (“old”) USP Monograph.

The results of these studies reinforce FDA’s previous recommendation for healthcare professionals to exercise clinical judgment in determining the dose of heparin for a patient and consider the clinical circumstances where the potency decrease may require dosage adjustments and more frequent monitoring.

Advisory Posted on 10/01/2009
FDA notified healthcare professionals and patients of a change to heparin, effective October 1, 2009, which will include a new reference standard and test method used to determine the potency of the drug and able to detect impurities that may be present in heparin. The change, which will also harmonize the USP unit dose with the WHO International Standard unit dose, will result in approximately a 10% reduction in the potency of the heparin marketed in the United States.

This may have clinical significance in some situations, such as when heparin is administered as a bolus intravenous dose and an immediate anticoagulant effect is clinically important.

Healthcare providers should be aware of the decrease in heparin potency as they monitor the anticoagulant effect of the drug; more heparin may be required to achieve and maintain the desired level of anticoagulation in some patients.

There will be simultaneous availability of heparin manufactured to meet the “old” and “new” USP monograph, with potential differences in potency. Products using the new “USP unit” potency definition are anticipated to be available on or after October 8.

FDA is working with the manufacturers of heparin to ensure that an appropriate identifier is placed on heparin made under the new USP monograph. Most manufacturers will place an “N” next to the lot number. FDA is also working with the heparin manufacturers to study the impact of this variation in potency and will make the results available when the studies have concluded.

see also:

Heparin Complications Have you experienced health complications from Heparin? Get Legal Info
Numerous health complications are associated with tainted Heparin

Adverse Reactions FDA Reports Adverse Reactions Related to Heparin--Free Lawsuit Info
FDA Monitors Contaminated Heparin and Adverse Reactions in Patients

FDA Health Advisory FDA Issues Advisory on Heparin Due to Health Risks--Free Lawsuit Info
Did You Suffer Adverse Reaction After Heparin Injection? Lawsuit info